Multiple myeloma is the second most common type of blood cancer, ... There are also several precancerous conditions that can sometimes lead to multiple myeloma. 1. Light Chain Myeloma.

Light chain multiple myeloma Another name for LCMM is “Bence-Jones myeloma,” after the doctor who discovered the disease. Around 15% of people with MM have LCMM.

If the ratio of the two types of free light chains is out of balance, it’s a sign of multiple myeloma. Myeloma cells. If your doctor tests your bone marrow, they’ll look for myeloma cells there.

In this exclusive MedPage Today video, investigator Shahzad Raza, MD, of the Cleveland Clinic Cancer Institute, explains why ...

For patients with multiple myeloma, the use of novel agents in first-line triplet and quadruplet induction regimens -- with or without high-dose therapy and autologous stem cell transplant (ASCT) -- ...

Serum free light chain assay test: Normally, the light chains kappa and lambda have about equal numbers of each in the blood. If one is higher than the other, however, it can be a sign of myeloma.

"Studies show that [multiple] myeloma is associated with more than 400 canonical somatic mutations per patient, and the most commonly mutated genes include immunoglobulin heavy chain and light ...

Monoclonal free light chains (FLCs) frequently cause rapidly progressive renal failure in patients with multiple myeloma. Immunoassays which provide quantitative measurement of FLCs in serum, have ...

Light-Chain Multiple Myeloma: A Diagnostic Challenge C Silva and others Cureus. 2021 Volume 13, Issue 10, e19131. An Overview of Light Chain Multiple Myeloma: Clinical Characteristics and Rarities, ...

Conoley, A. J., et al. (2025). Therapy-related B-lymphoblastic Leukemia Following Treatment for Multiple Myeloma with Unusual Surface Light Chain Expression: A Case Report.

Background The development of serum immunoassays for the measurement of immunoglobulin free light chains has led to a paradigm shift in the diagnosis, assessment and monitoring of patients with ...

Therapy-related B-lymphoblastic leukemia (B-ALL) following treatment for multiple myeloma is a rare occurrence. Despite its rarity and the lack of recognition by the World Health Organization as a ...